You need JavaScript to view this

Development of radiopharmaceuticals

Abstract

To overcome many problems caused by external radiation therapy, we have developed a new agent for internal radiation therapy, which is administered directly to the lesions and irradiate {beta}-rays resulting in maximized therapeutic effect and minimized radiation damage to normal tissues or organs to nearby. In the same reasons, we have also developed a new radioactive patch for the treatment of skin cancer using {beta}-emitting radionuclide. We prepared for {sup 166}Ho-chitosan complex ({sup 166}Ho-CHICO) which is potential radiopharmaceuticals for the treatment of liver cancer, peritoneal cancer metastasized from stomach cancer, ovarian cancer, and rheumatoid arthritis in knee joints. We carried out various experiments such as evaluation of absorbed dosimetry, studies on absorption, distribution, metabolism, and excretion (ADME) and clinical trials with {sup 166}Ho-CHICO. For commercialization of {sup 166}Ho-CHICO, we evaluated its toxicity, efficacy and safety, and then prepared documents for submission to the Mininstry of Health and Welfare to get license as an investigational new drug. {sup 166}Ho-Patch for skin cancer treatment was prepared by neutron irradiation of pre-made non-radioactive {sup 165}Ho-Patch. We evaluated the efficacy and safety of {sup 166}Ho-Patch in the treatment of skin cancer using an animal model and in clinical cases. (author). 49 refs., 15 tabs.,  More>>
Publication Date:
Sep 01, 1997
Product Type:
Technical Report
Report Number:
KAERI/RR-1761/96
Reference Number:
SCA: 550603; PA: AIX-29:000898; EDB-98:076588; SN: 98001898906
Resource Relation:
Other Information: PBD: Sep 1997
Subject:
55 BIOLOGY AND MEDICINE, BASIC STUDIES; EPITHELIOMAS; EXTERNAL IRRADIATION; HOLMIUM COMPLEXES; HOLMIUM 166; INTERNAL IRRADIATION; RADIOPHARMACEUTICALS; RHEUMATIC DISEASES
OSTI ID:
621825
Research Organizations:
Korea Atomic Energy Research Institute, Taejon (Korea, Republic of)
Country of Origin:
Korea, Republic of
Language:
Korean
Other Identifying Numbers:
Other: ON: DE98607863; TRN: KR9700328000898
Availability:
INIS; OSTI as DE98607863
Submitting Site:
KRN
Size:
372 p.
Announcement Date:
Jul 22, 1998

Citation Formats

Park, Kyung Bae, Kim, J R, Shin, B C, Kim, Y M, Cho, U K, Han, K H, Chung, Y J, Shin, H Y, and Hong, S B. Development of radiopharmaceuticals. Korea, Republic of: N. p., 1997. Web.
Park, Kyung Bae, Kim, J R, Shin, B C, Kim, Y M, Cho, U K, Han, K H, Chung, Y J, Shin, H Y, & Hong, S B. Development of radiopharmaceuticals. Korea, Republic of.
Park, Kyung Bae, Kim, J R, Shin, B C, Kim, Y M, Cho, U K, Han, K H, Chung, Y J, Shin, H Y, and Hong, S B. 1997. "Development of radiopharmaceuticals." Korea, Republic of.
@misc{etde_621825,
title = {Development of radiopharmaceuticals}
author = {Park, Kyung Bae, Kim, J R, Shin, B C, Kim, Y M, Cho, U K, Han, K H, Chung, Y J, Shin, H Y, and Hong, S B}
abstractNote = {To overcome many problems caused by external radiation therapy, we have developed a new agent for internal radiation therapy, which is administered directly to the lesions and irradiate {beta}-rays resulting in maximized therapeutic effect and minimized radiation damage to normal tissues or organs to nearby. In the same reasons, we have also developed a new radioactive patch for the treatment of skin cancer using {beta}-emitting radionuclide. We prepared for {sup 166}Ho-chitosan complex ({sup 166}Ho-CHICO) which is potential radiopharmaceuticals for the treatment of liver cancer, peritoneal cancer metastasized from stomach cancer, ovarian cancer, and rheumatoid arthritis in knee joints. We carried out various experiments such as evaluation of absorbed dosimetry, studies on absorption, distribution, metabolism, and excretion (ADME) and clinical trials with {sup 166}Ho-CHICO. For commercialization of {sup 166}Ho-CHICO, we evaluated its toxicity, efficacy and safety, and then prepared documents for submission to the Mininstry of Health and Welfare to get license as an investigational new drug. {sup 166}Ho-Patch for skin cancer treatment was prepared by neutron irradiation of pre-made non-radioactive {sup 165}Ho-Patch. We evaluated the efficacy and safety of {sup 166}Ho-Patch in the treatment of skin cancer using an animal model and in clinical cases. (author). 49 refs., 15 tabs., 36 figs.}
place = {Korea, Republic of}
year = {1997}
month = {Sep}
}